Search
SectionsIndex
  • Behavior
  • Circulatory System
  • Clinical Pathology and Procedures
  • Digestive System
  • Emergency Medicine and Critical Care
  • Endocrine System
  • Exotic and Laboratory Animals
  • Eye and Ear
  • Generalized Conditions
  • Immune System
  • Integumentary System
  • Management and Nutrition
  • Metabolic Disorders
  • Musculoskeletal System
  • Nervous System
  • Pharmacology
  • Poultry
  • Reproductive System
  • Respiratory System
  • Toxicology
  • Urinary System
  • Zoonoses
ABCDEFGHI
JKLMNOPQR
STUVWXYZ
In This Topic
Digestive System
Hepatic Disease in Small Animals
Hepatotoxins in Small Animals
Back to Top
Resources
  • About The Merck Veterinary Manual
  • Reference Guides
  • Multimedia
Manuals available online
'/home/index.html' + bookPageLink
 
'/vet/index.html'
These and other Manuals available
in print, online, and as mobile applications.

See more at MerckManuals.com
Sections in Veterinary Professionals
  • Behavior
  • Circulatory System
  • Clinical Pathology and Procedures
  • Digestive System
  • Emergency Medicine and Critical Care
  • Endocrine System
  • Exotic and Laboratory Animals
  • Eye and Ear
  • Generalized Conditions
  • Immune System
  • Integumentary System
  • Management and Nutrition
  • Metabolic Disorders
  • Musculoskeletal System
  • Nervous System
  • Pharmacology
  • Poultry
  • Reproductive System
  • Respiratory System
  • Toxicology
  • Urinary System
  • Zoonoses
Chapters in Digestive System
  • Digestive System Introduction
  • Congenital and Inherited Anomalies of the Digestive System
  • Dental Development
  • Dentistry
  • Pharyngeal Paralysis
  • Diseases of the Rectum and Anus
  • Enteric Campylobacteriosis
  • Intestinal Chlamydial Infections
  • Salmonellosis
  • Tyzzer's Disease
  • Amebiasis
  • Coccidiosis
  • Cryptosporidiosis
  • Giardiasis
  • Diseases of the Mouth in Large Animals
  • Diseases of the Esophagus in Large Animals
  • Gastrointestinal Ulcers in Large Animals
  • Diseases of the Ruminant Forestomach
  • Diseases of the Abomasum
  • Acute Intestinal Obstructions in Large Animals
  • Colic in Horses
  • Intestinal Diseases in Ruminants
  • Intestinal Diseases in Horses and Foals
  • Intestinal Diseases in Pigs
  • Gastrointestinal Parasites of Ruminants
  • Gastrointestinal Parasites of Horses
  • Gastrointestinal Parasites of Pigs
  • Fluke Infections in Ruminants
  • Hepatic Disease in Large Animals
  • Malassimilation Syndromes in Large Animals
  • Abdominal Fat Necrosis
  • Diseases of the Mouth in Small Animals
  • Diseases of the Esophagus in Small Animals
  • Diseases of the Stomach and Intestines in Small Animals
  • The Exocrine Pancreas
  • Gastrointestinal Parasites of Small Animals
  • Hepatic Disease in Small Animals
  • Vomiting
Topics in Hepatic Disease in Small Animals
  • Overview of Hepatic Disease in Small Animals
  • Hematology in Hepatic Disease in Small Animals
  • Coagulation Tests in Hepatic Disease in Small Animals
  • Enzyme Activity in Hepatic Disease in Small Animals
  • Other Serum Biochemical Measures in Hepatic Disease in Small Animals
  • Hepatic Function Tests in Small Animals
  • Imaging in Hepatic Disease in Small Animals
  • Cholecystocentesis in Hepatic Disease in Small Animals
  • Liver Cytology in Small Animals
  • Liver Biopsy in Small Animals
  • Pathologic Changes in Bile in Small Animals
  • Nutrition in Hepatic Disease in Small Animals
  • Fulminant Hepatic Failure in Small Animals
  • Hepatic Encephalopathy in Small Animals
  • Portal Hypertension and Ascites in Small Animals
  • Portosystemic Vascular Malformations in Small Animals
  • Acquired Portosystemic Shunts in Small Animals
  • Other Hepatic Vascular Disorders in Small Animals
  • Hepatotoxins in Small Animals
  • Infectious Diseases of the Liver in Small Animals
  • Feline Hepatic Lipidosis
  • Biliary Cirrhosis in Small Animals
  • Canine Cholangiohepatitis
  • Canine Chronic Hepatitis
  • Lobular Dissecting Hepatitis in Small Animals
  • Canine Vacuolar Hepatopathy
  • Metabolic Diseases Affecting the Liver in Small Animals
  • Hepatocutaneous Syndrome in Small Animals
  • Nodular Hyperplasia in Small Animals
  • Hepatic Neoplasia in Small Animals
  • Miscellaneous Liver Diseases in Small Animals
  • Diseases of the Gallbladder and Extrahepatic Biliary System in Small Animals
  • Cholecystitis in Small Animals
  • Canine Gallbladder Mucocele
  • Other Disorders of the Gallbladder in Small Animals
  • Other Disorders of Bile Ducts in Small Animals
  • Extrahepatic Bile Duct Obstruction in Small Animals
  • Cholelithiasis in Small Animals
  • Biliary Tree Rupture and Bile Peritonitis in Small Animals
  • Feline Cholangitis/Cholangiohepatitis Syndrome
  • Hepatobiliary Fluke Infection in Small Animals
 
  • Merck Manual
  • >
  • Veterinary Professionals
  • >
  • Digestive System
  • >
  • Hepatic Disease in Small Animals
  • 4
 
Hepatotoxins in Small Animals

Share This

While many drugs have been associated with hepatic dysfunction, their influence on liver pathology varies depending on the pathomechanism of liver injury and the acinar zone of metabolic or circulatory disturbance.

Primidone, phenytoin, and phenobarbital can cause acute fulminant liver failure, chronic cholestatic liver disease, or a diffuse progressive degenerative VH leading to epidermal metabolic necrosis (also known as necrolytic migratory erythema or phenobarbital effect). VH (steroid hepatopathy) is usually a benign, reversible change associated with high-dose, longterm glucocorticoid therapy. However, glucocorticoids given in excessive doses can cause a diffuse severe degenerative VH causing jaundice in dogs and HL in cats. Increases in AP and, to a lesser extent, ALT are seen as soon as 2 days after glucocorticoid administration in dogs but not in cats.

Lomustine, a chemotherapeutic agent in dogs, causes an idiosyncratic unpredictable and progressive hepatitis culminating in cirrhosis.

Danazol, an impeded androgen, can cause idiosyncratic reversible jaundice in dogs.

Androgenic anabolics can cause HL in inappetent cats or cats fed a protein-restricted diet.

Thiacetarsamide, previously used to treat dirofilariasis, causes hepatotoxicity owing to its arsenical content.

Toxicity is associated with increased ALT activity and in some dogs, jaundice. High liver enzymes were used as an indication to suspend therapy; thereafter hepatic injury resolved. Mebendazole-associated idiosyncratic hepatotoxicity in dogs was observed to cause fatal acute hepatic necrosis or chronic hepatitis. Chronic oxibendazole-diethylcarbamazine administration in dogs was shown to cause increased ALT and AP activity, hyperbilirubinemia, periportal hepatitis and fibrosis. Progressive injury and clinical signs resolved in many dogs after drug discontinuation.

Many NSAID are mitochondrial toxins, and some are associated with idiosyncratic acute hepatocellular toxicity. In particular, carprofen was shown to cause idiosyncratic hepatic necrosis in some dogs, particularly Labrador Retrievers. Dogs may recover fully if toxicity is recognized early and the drug administration suspended. In dogs, trimethoprim-sulfadiazine also can cause idiosyncratic hepatotoxicity that may involve an immune-mediated component. A reversible cholestatic hepatopathy or acute/subacute massive fatal hepatic necrosis has been observed, sometimes after only a few treatments at a recommended dose. Halothane and methoxyflurane also can be associated with a sensitization reaction leading to hepatic necrosis in dogs. Xylitol may be an intrinsic hepatotoxin for dogs, with ingestion of small doses leading to intractable hypoglycemia and lethal hepatic failure. Toxicity may lead to death before liver enzyme activity increases.

Tetracyclines can rarely lead to idiosyncratic necrosis in dogs and cats and have been shown to augment hepatocellular lipid accumulation. Itraconazole and ketoconazole in dogs and cats can cause idiosyncratic hepatotoxicity associated with high liver enzyme activity and jaundice. Clinical signs resolve when these drugs are withdrawn.

Acetaminophen predictably causes centrilobular hepatic necrosis in dogs at dosages >200 mg/kg. Methemoglobinemia is also seen. Toxicity in cats is seen acutely at a much lower dosage (56 mg/kg), with hematologic signs predominating (eg, methemoglobinemia and Heinz body hemolysis). (see Toxicities from Human Drugs.)

Methimazole hepatotoxicity in cats appears to be idiosyncratic but also may involve immune mechanisms; hepatic degeneration and necrosis may develop. Clinical features include inappetence, jaundice, and increased liver enzyme (ALT, AST) activity that resolve after drug discontinuation.

In cats, griseofulvin-associated hyperbilirubinemia and increased ALT also appear to be idiosyncratic. Clinical signs and liver injury are reversible upon drug discontinuation. Idiopathic diazepam toxicity in cats causes fulminant hepatic failure associated with panlobular necrosis; signs of toxicity are evident within several days of initial drug administration. Toxicity has mainly been observed with medication given PO for behavior modification or to treat feline lower urinary tract disease. Idiosyncratic diazepam hepatotoxicity is usually fatal in cats. Proactive monitoring of liver enzymes can identify adverse reactions early in their course allowing for prompt drug discontinuation. Similar toxicity has also been observed with oxazepam.

Specific xenobiotics toxic to the liver include aflatoxins, the toxins derived from amanita mushrooms, blue-green algae (microcystin), and cycads (sago palm, commonly sold as bonsai plants). While toxicities are rare, each can cause lethal hepatic necrosis. Other chemicals reported to be hepatotoxic include heavy metals, certain herbicides, fungicides, insecticides, and rodenticides. (Also see Toxicology Introductionet seq.)

Important steps to minimize absorption of ingested toxins or overdose of oral drugs include vigorous decontamination of the stomach and intestines by gastric lavage, induced vomiting, and decreasing enteric toxin absorption. Vomiting can be induced within 30 min up to to 2 hr after ingestion by administering hydrogen peroxide (5 mL, PO, every 15 min), syrup of ipecac (1–2 mL/kg), or apomorphine. Activated charcoal without sorbitol (2 g/kg, PO, repeated every 6–8 hr) may be administered to reduce absorption only if the animal is conscious. Activated charcoal may also be administered as a high-retention enema. Gastric lavage is important to prevent absorption in unconscious animals. High-cleansing colonic enemas should also be done, using polyionic warmed fluids in dehydrated animals. If there is no specific treatment for a hepatotoxin, judicious supportive care should be provided.

Last full review/revision March 2012 by Sharon A. Center, DVM, DACVIM

Buy the Book

Back to Top

Previous: Other Hepatic Vascular Disorders in Small Animals

Next: Infectious Diseases of the Liver in Small Animals

Audio
Figures
Photographs
Sidebars
Tables
Videos

Copyright     © 2010-2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.    Privacy    Terms of Use